Skip to main content
. 2024 May 30;9(13):e174329. doi: 10.1172/jci.insight.174329

Figure 4. Uric acid inhibits the microtubule-destabilizing activity of rigosertib.

Figure 4

(A) Western blot of soluble α-tubulin from SUM149 cells treated with increasing doses of rigosertib (0.1 μM, 0.5 μM, and 1 μM) for 4 hours in RPMI and HPLM. (B) Quantification of Western blots from A. Data are represented as mean ± SD from 3 independent experiments. ****P < 0.0001, *P < 0.05 by 1-way ANOVA followed by Tukey’s multiple-comparison test. (C) Western blot of soluble α-tubulin from SUM149 treated with increasing doses of rigosertib (0.1 μM, 0.5 μM, and 1 μM) for 4 hours in HPLM and HPLM – UA. (D) Quantification of Western blots from C. Data are represented as mean ± SD from 3 independent experiments. *P < 0.05 by 1-way ANOVA followed by Tukey’s multiple-comparison test. (E and F) Dose-response curves of HCC1806 (E) and SUM149 (F) cells treated with pharmaceutical-grade rigosertib in RPMI versus HPLM. (G and H) Dose-response curves of a panel of renal cancer cell lines treated with pharmaceutical-grade rigosertib in RPMI (G) versus RPMI + UA (H). (I) Western blot of soluble and pellet α-tubulin from 786-O cells treated with increasing doses (5 nM, 50 nM, 100 nM, 500 nM, 1,000 nM) of pharmaceutical-grade rigosertib for 4 hours in RPMI and RPMI + UA. (J) Quantification of Western blots from I. Data are represented as means ± SD of 3 independent experiments. *P < 0.05 by 2-way ANOVA.